← Back to Search

LungTalk for Increasing Lung Cancer Screening

N/A
Recruiting
Led By Lisa Carter-Bawa, PhD
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals who currently smoke or quit smoking within the past 15 years
Be older than 18 years old
Must not have
Has ever been diagnosed with lung cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months from baseline survey completion
Awards & highlights

Summary

This trial uses a program called LungTalk and Facebook ads to encourage high-risk individuals to get screened for lung cancer. The goal is to increase awareness and motivate people to undergo screening. By targeting those at higher risk, the intervention aims to catch lung cancer early when it is more treatable.

Who is the study for?
The INSPIRE-Lung Study is for individuals who have a history of heavy smoking (at least 20 pack-years), including current smokers or those who quit within the last 15 years. It's not for people who've already had lung cancer screening, are being monitored for lung nodules, have been diagnosed with lung cancer, or have impaired decision-making.
What is being tested?
This study tests 'LungTalk', a communication intervention aimed at increasing lung cancer screening rates among high-risk groups using Facebook-targeted advertisements. It compares LungTalk to standard practices without tailored interventions.
What are the potential side effects?
Since this trial focuses on communication strategies rather than medical treatments, there are no direct side effects like you'd expect from drugs or surgeries. However, participants may experience emotional or psychological responses to the content.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a current smoker or quit smoking within the last 15 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with lung cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months from baseline survey completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months from baseline survey completion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effectiveness of LungTalk - Knowledge Assessment
Effectiveness of LungTalk - Occurrence of a Patient-Clinician Discussion
Effectiveness of LungTalk - Perceived Barriers
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tailored health communication intervention (LungTalk)Experimental Treatment1 Intervention
Participants will receive the tailored health intervention "LungTalk". LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation.
Group II: Non-tailored InterventionActive Control1 Intervention
Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for lung cancer include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy kills rapidly dividing cells, including cancer cells, but also affects normal cells, leading to side effects. Targeted therapy uses drugs to specifically target genetic mutations or proteins involved in cancer cell growth and survival, offering a more precise treatment with potentially fewer side effects. Immunotherapy enhances the body's immune system to recognize and destroy cancer cells. These treatments are vital for lung cancer patients as they provide multiple strategies to control or eliminate cancer, improving survival rates and quality of life. Increasing lung cancer screening uptake through communication strategies like LungTalk and Facebook-targeted Advertisement is crucial for early detection and timely treatment, which can significantly improve patient outcomes.
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.The management of non-small-cell lung cancer: a case history.

Find a Location

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor
135 Previous Clinical Trials
29,794 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,872 Previous Clinical Trials
41,012,364 Total Patients Enrolled
Lisa Carter-Bawa, PhDPrincipal InvestigatorHackensack Meridian Health
4 Previous Clinical Trials
872 Total Patients Enrolled

Media Library

LungTalk Clinical Trial Eligibility Overview. Trial Name: NCT05824273 — N/A
Lung Cancer Research Study Groups: Tailored health communication intervention (LungTalk), Non-tailored Intervention
Lung Cancer Clinical Trial 2023: LungTalk Highlights & Side Effects. Trial Name: NCT05824273 — N/A
LungTalk 2023 Treatment Timeline for Medical Study. Trial Name: NCT05824273 — N/A
~333 spots leftby Jul 2027